With decades of experience in drug discovery driven by strong customer relationships, PerkinElmer has developed an excellent product portfolio of drug discovery tools for complete solutions serving all parts of the discovery workflow. As a strategic partner, PerkinElmer's goal is to support these workflows by its superior offering of drug discovery technologies, ranging from instruments, reagents, data analysis and bioinformatics tools for drug discovery to first-class customer service and support. PerkinElmer works with the customer to enable deeper biological disease understanding and support the application of novel innovative technologies to address unmet medical needs and provide evidence for target engagement. Discover how PerkinElmer can support your research from DNA/RNA- to protein/cell-based solutions.
Identify and Validate Your Disease-Relevant Targets For Unmet Medical Needs:
Selecting the right target remains one of the most important decisions and investments that companies make in the drug discovery process. Pursuing the wrong target can waste significant amounts of time and money, and eventually result in failure of the program. To ensure downstream success, targets must be accurately identified and thoroughly validated by demonstrating a strong link between target and disease with differentiated efficacy alongside with available and predictive biomarkers.
When combined, our in vitro and in vivo technologies provide data on the biological entity associated with disease of interest and if appropriate modulation of target anticipated impacts disease in a consistent manner to make the most accurate prediction of target relevance in human disease.
Find Your Hits for Disease-Relevant Targets:
Once a target has been selected, the next stage of the drug discovery process involves developing biologically-relevant assays to identify active molecules in biochemical and/or cell-based assays. To maximize the hit finding probability, multiple screening techniques are required to engage and confirm findings orthogonally.
PerkinElmer’s screening solutions can help you identify and confirm your drug compounds quickly and efficiently to advance it to the next stage. With our reliable and validated screening assays, multimode plate readers, state-of-the-art imaging high-content instruments, integrated automation for liquid handling, and powerful analysis software, our portfolio brings consistent, accurate, physiologically relevant results for faster discoveries and impactful breakthroughs to gain more confidence in your discovery.
Optimize Your Lead Series for Highly Validated Targets:
Moving hits into highly quality lead series is the main goal of lead optimization to gain the broadest possible chemical insight. In this phase, analogs of leads are prepared and synthesized to improve biological properties for clinical development. Earlier toxicity studies eliminates the risk of molecular-related safety issues as a cause of project closure. Improvements are critical and sometimes challenging for novel, demanding but highly validated targets.
With our validated screening assays and multimode plate readers, state-of-the-art imaging instruments for High Content as well as In Vivo, integrated automation for liquid handling, and powerful analysis software, our portfolio brings consistent, accurate, physiologically relevant results for faster discoveries and impactful breakthroughs to gain more confidence in your discovery.